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Swinepox virus (SPV) has been proposed as a potential vector for generating recombinant vaccines for swine. However,
little is known about important aspects of SPV biology, such as the functionality of SPV promoters or the host range of SPV.
Using a transient expression assay, well-characterized vaccinia virus promoters were shown to be active in cells infected
with SPV. A recombinant SPV expressing b-galactosidase (b-gal) was constructed and characterized. The E. coli LacZ gene
was placed under the control of a strong vaccinia synthetic early/late promoter and was inserted by homologous recom-
bination in a noncoding region of the SPV genome. The recombinant SPV expressing b-gal was used to characterize the host
range of the virus by measuring protein expression and virus production in different cell lines. In general, SPV expressed
more protein and grew more efficiently than vaccinia virus in porcine cell lines. Surprisingly, the recombinant SPV was able
to infect and replicate in several cell lines of nonswine origin. The virus directed regulated early and late gene expression
of b-gal in those cells and formed blue plaques in cell monolayers in the presence of X-gal. Upon infection with the
recombinant SPV, there was a significant level of viral replication, and the virus can be serially passaged in some nonswine
cell lines. The data presented suggest that despite the strict host tropism of SPV, the virus exhibits a relatively broad host
range in cell culture. © 1998 Academic Press
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INTRODUCTION
Poxviridae are large DNA containing viruses that char-
acteristically replicate in the cytoplasm of the host cell,
where both DNA replication and RNA transcription take
place. The coding of many enzymes involved in virus rep-
lication and gene expression makes the poxviruses rela-
tively independent of the corresponding cellular functions.
The best studied poxvirus, vaccinia virus (VV), has a wide
host range, being able to infect many different mammalian
species. Also, VV readily infects cell lines derived from
widely different species. VV host range is modulated by at
least five genes: four encoded by VV or rabbitpox virus and
a third encoded by the closely related cowpox virus (Beattie
et al., 1996; Brooks et al., 1995; Chang et al., 1995; Drillien et
al., 1981, 1978; Gillard et al., 1985; Perkus et al., 1990).
Poxviruses have a potential as vectors for immunization
against human and veterinary diseases. One important
characteristic of vectors, in particular for animal vaccines, is
the host restriction of the viral vector itself. Ideally, a recom-
binant veterinary vaccine should replicate to some extent in
the target animal, in order to increase the potency, and be
unable to be transmitted to other species. Thus, host re-
striction of poxviruses with potential as vectors is of impor-
tance in the development of safe and potent vaccine
vectors.
Swinepox virus (SPV) is the only member of the genus
Suipoxvirus, belonging to the family Poxviridae. SPV’s nat-
ural host is the pig, where it causes a usually mild, gener-
alized infection (for review, see (Mahnel, 1989)). The natural
characteristics of SPV infection make it well suited for the
development of recombinant vaccines, and its use to vac-
cinate against other diseases has been considered (Tuboly
et al., 1993; van der Leek et al., 1994). However, little is
known regarding the biology of SPV, and more information
is needed to optimally address the critical issues regarding
vaccine vector safety and immunogenicity. SPV can be
grown in porcine primary cell cultures and can be adapted
to pig cell lines. SPV has been experimentally inoculated in
different species and displays a narrow host range in vivo
(Datt, 1964; Schwarte and Biester, 1941). In addition, the
virus has been reported to infect only cells of swine origin
(Garg and Meyer, 1972; Kasza et al., 1960).
In this work we report the isolation and characterization
of a recombinant SPV expressing b-gal and show a de-
tailed study of the behavior of the virus in cell cultures of
porcine and nonporcine origin.
RESULTS
Transient expression of b-gal
Because there is no functional information available
regarding SPV promoter sequences, we initially tested
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our LacZ cassettes in a transient expression assay to
determine whether VV promoters are functional in SPV-
infected cells. Two plasmids were used in these assays:
plasmid pSC11 (Chakrabarti et al., 1985), in which the
LacZ gene is under the control of the late VV promoter
P11, and plasmid pUCLZ-7 (see Fig. 1), which carries the
LacZ gene under the control of a synthetic VV early/late
promoter, PE/L. Both plasmids were tested for their ability
to direct expression of b-gal in SPV- or VV-infected PK-15
cells. As expected, b-gal expression was dependent on
the presence of viral transcriptional machinery, since no
b-gal expression was detected after transfection of ei-
ther plasmid in uninfected cells (data not shown). Similar
levels of b-gal were detected in lysates from either SPV
or VV infected cells (Fig. 2), indicating good cross-rec-
ognition of VV promoters by the SPV RNA polymerase.
Levels of b-gal in cells transfected with pUCLZ-7 were
about 50% higher than those obtained with pSC11. Given
that SPV efficiently recognized VV PE/L promoter, we
selected this promoter for the development of a SPV
cloning and expression system.
Design of a SPV virus insertion/expression system
A cloning system that would allow the construction of
SPV recombinants was developed. The system was de-
signed to mediate insertion of foreign genes into the SPV
genome by homologous recombination. We constructed
plasmid pGSPV-LZ4, containing SPV flanking sequences,
the PE/L promoter, and the LacZ gene (Fig. 1). This plas-
mid was devised to direct the insertion of the PE/L-LacZ
cassette into a 367-nucleotide-long intergenic region lo-
cated between ORFs C18L and C19L in the left terminal
region of the SPV genome (Massung et al., 1993). Foreign
genes can be inserted in pGSPV-LZ4 in place of the LacZ
gene by using a BamHI site located downstream of the
promoter.
Isolation of a recombinant SPV expressing b-gal
Similar to systems developed for the construction of
other recombinant poxviruses, infection/transfection was
used to allow insertion of the foreign gene by homolo-
gous recombination. Plasmid pGSPV-LZ4 was trans-
fected into PK-15 cells infected with SPV. After 6–7 days,
dilutions of the progeny virus were used to infect fresh
monolayers of ESK-4 cells, which were stained with X-gal
to detect b-gal expression. Blue, b-gal-expressing virus
plaques appeared at an approximate frequency of 0.05%
FIG. 2. Transient expression of b-gal. PK-15 cells infected with VV (l)
or SPV () at a m.o.i. of 5 PFU per cell were transfected with different
amounts of plasmid pUCLZ-7 with b-gal under control of a synthetic E/L
promoter (A) or a plasmid (pSC11) with b-gal under control of a late
promoter (B). After 4 days, the cells were harvested and assayed for
b-galactosidase activity (expressed as nmoles of ONPG hydrolyzed in
1 min at 37°C).
FIG. 1. Design of a SPV insertion vector. Two SPV DNA segments (LF
and RF) close to the left end of the genome were amplified by PCR and
inserted into plasmid pGEM-7 to generate pGSPV. To construct the
PE/L-LacZ cassette, the promoter sequence was first generated by
annealing two synthetic oligonucleotides and was cloned in plasmid
pUC-19. Subsequently, the coding sequence of the LacZ gene was
inserted downstream of the promoter to create pUCLZ-7. Finally, plas-
mid pGSPVLZ-4 was generated by inserting the PE/L-LacZ cassette
between the SPV sequences in pGSPV. LF, left flanking sequence; RF,
right flanking sequence.
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with respect to the parental white plaques. Several SPV
plaques positive for b-gal expression were picked and
reisolated by consecutive rounds of plaque purification
in the presence of X-gal. Four to five successive plaque
purifications were necessary to dilute out parental virus
not displaying the blue plaque phenotype. In subsequent
plaque assays, exclusively blue plaques were detected
(not shown), indicating that the recombinant SPV had the
LacZ cassette stably inserted in the viral genome. One
virus clone, SPV-LZ4, was selected for further character-
ization. Both the growth rate and the plaque size pheno-
type of SPV-LZ4 in ESK-4 cells were similar to those of
the parental virus (not shown). The genomic structure of
SPV-LZ4 DNA, analyzed by PCR using oligonucleotide
primers external to the insertion site and flanks, con-
firmed that a DNA fragment of the correct length had
been inserted into the intended location in the SPV ge-
nome (not shown).
In parallel, the same LacZ cassette from plasmid pU-
CLZ-7 was inserted in the genome of VV. A recombinant
virus expressing b-gal, VV-LZ2, was isolated by plaque
purification.
Expression of b-gal by SPV-LZ4 and VV-LZ2 in
different cell lines
To initially characterize the host species restriction of
SPV in vitro, we measured b-gal expression in cells in-
fected with SPV-LZ4. Monolayers of 11 cell lines from six
different mammalian species were infected with either VV-
LZ2 or SPV-LZ4, in the presence or the absence of cytosine
arabinoside (araC), an inhibitor of DNA replication. As ex-
pected from the broad host range of VV, enzyme activity
was detected in a variety of VV-LZ2-infected cells, although
to widely different levels (Table 1). The highest levels of
b-gal activity were obtained in cell lines that are routinely
used to grow VV-like HeLa, CV-1, or BHK-21 and also in the
rabbit cell line SIRC. About 10-fold less b-gal activity was
present in lysates from three of the porcine cell lines in-
cluded in this study (ESK-4, ST, and IBRS). When DNA
synthesis was inhibited by addition of araC, protein expres-
sion was significantly reduced, although to different levels
in different cell lines. The observed effect of araC is con-
sistent with the presence of both early and late promoter
activities in PE/L.
b-Gal expression in porcine cell lines was higher
when they were infected with SPV-LZ4 than when in-
fected with VV-LZ2. Significantly, SPV-LZ4 induced ap-
proximately 10-fold more expression of the reporter gene
than VV-LZ2 in three of the four pig cell lines tested
(ESK-4, ST, and IBRS). In addition, detectable levels of
b-gal activity were also present in the lysates of SPV-
LZ4-infected cells of nonporcine origin. Virus-induced
expression of b-gal in CV-1 cells was comparable to that
of infected swine cell lines, and significant expression
levels were also present in BHK-21, HeLa, and BSC-1
cells. Nevertheless, it should be noted that SPV-LZ4
induced much less b-gal expression than VV-LZ2 in the
cell lines of nonswine origin. As in the case of VV-LZ2-
infected cells, addition of araC produced a reduction in
the levels of b-gal in SPV-LZ4-infected cells, suggesting
functional temporal promoter regulation of b-gal expres-
sion in those cells.
Bovine MDBK cells rendered the lowest levels of b-gal
expression upon infection with either SPV or VV recom-
binant viruses. This result is not surprising, since this cell
line was reported to be nonpermissive for SPV infection
(Foley et al., 1991; Garg and Meyer, 1972) and does not
TABLE 1
b-Galactosidase Activity in Different Cell Lines Infected with SPV-LZ4 or VV-LZ2
Cell line Origin
b-Galactosidase activitya
VV-LZ2 SPV-LZ4
1 AraCb 2AraC 1AraC 2AraC
PK-15 Porcine 55 6 2.6 1,429 6 39 112 6 14.6 2,120 6 92
ESK-4 Porcine 18 6 0.1 250 6 3 74 6 3.0 1,727 6 45
ST Porcine 16 6 0.6 141 6 3 112 6 0.4 1,216 6 31
IBRS Porcine 12 6 0.2 141 6 6 111 6 0.8 1,768 6 32
HeLa Human 47 6 7.8 2,401 6 120 178 6 4.1 661 6 15
CV-1 Monkey 106 6 0.8 2,371 6 29 157 6 4.0 1,845 6 114
BSC-1 Monkey 97 6 2.0 858 6 77 114 6 4.2 456 6 20
BHK-21 Hamster 144 6 0.2 2,489 6 58 183 6 23.8 967 6 23
SIRC Rabbit 25 6 0.9 2,489 6 225 59 6 3.9 285 6 9
RK-13 Rabbit 30 6 1.6 978 6 57 69 6 2.3 263 6 31
MDBK Bovine 59 6 0.3 84 6 1 111 6 5.6 140 6 2
a Expressed as nmoles of ONPG hydrolyzed in 1 min at 37°C per 5 3 104 cells.
b AraC was used at a final concentration of 40 mg/ml.
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support expression of VV late gene products (Hruby et
al., 1980).
The kinetics of b-gal expression was followed by de-
termining enzyme activity at different times postinfection
(Fig. 3). In agreement with previous studies on the syn-
thesis of SPV proteins (Massung and Moyer, 1991), b-gal
expression in SPV-LZ4-infected cells was delayed with
respect to those infected with VV-LZ2. Cells infected with
VV-LZ2 reached maximum levels of b-gal activity by 48 h
postinfection, whereas 72–96 h of infection was neces-
sary in SPV-LZ4-infected cells.
Replication of SPV-LZ4 and VV-LZ2 in different cell
lines
The observation that SPV induced gene expression in
a variety of cell lines does not necessarily indicate that
the virus can productively infect those cells, as exempli-
fied by avipoxviruses or certain strains of VV, such as
MVA, which are able to induce normal levels of gene
expression and DNA replication in cells that do not
produce infectious progeny (Paoletti, 1996; Somogyi et
al., 1993; Sutter and Moss, 1992). Since SPV is reportedly
restricted to swine in vivo, it was of interest to determine
whether SPV-LZ4 productively replicates in cell cultures
from nonporcine origin. Thus, we tested the ability of
SPV-LZ4 to grow in different cell lines and compared it to
VV-LZ2 (Fig. 4A). The results obtained paralleled the
gene expression data described above. As expected,
recombinant VV was able to multiply in all the cell lines
tested except in the nonpermissive MDBK cells. Similar
to the b-gal activity assays, a high level of replication of
VV-LZ2 occurred in HeLa, CV-1, BHK-21, and SIRC cells. A
lower level of VV replication occurred in three of the
porcine cell lines tested (ESK-4, ST, and IBRS). In con-
trast to VV, SPV-LZ4 replicated more efficiently in porcine
cell lines than in the nonporcine cell lines. Moreover, the
high efficiency of SPV-LZ4 replication in porcine cells
resulted in SPV-LZ4 final virus yields being similar or
even superior to VV-LZ2 yields in those cells.
Surprisingly, there were significant increases in virus
titers of SPV-LZ4 in CV-1, BHK-21, BSC-1, and HeLa cul-
tures over a 6-day infection period, indicating that SPV-
LZ4 was actively replicating in those cells. No virus
replication was apparent in MDBK and the rabbit cell
lines SIRC and RK-13, since titers were lower than those
of input virus. These results were not a particular feature
of the recombinant SPV, since similar results were ob-
tained when cell lines were infected with parental SPV
(data not shown).
We also determined the ability of SPV-LZ4 to undergo
serial passages in different cell lines. Six sequential
passages were performed as described under Materials
and Methods, and the virus titer was determined after
each round (Fig. 4B). Again, the results obtained paral-
leled those of gene expression and viral replication ex-
periments. Virus titers were maintained during passages
in the two porcine cell lines, PK-15 and ESK-4, as well as
in CV-1 and BHK-21, although viral titers in the latter
remained consistently lower. These results confirm viral
replication to different extents in several of the nonpor-
cine cell lines tested and indicate that the virus is not
readily adapted to nonpermissive cells.
Given that SPV is naturally restricted to pigs, the de-
tection of a certain degree of virus growth in cell lines of
nonporcine origin was unexpected. Virus yields in some
cells were low, particularly in the case of BSC-1 and
FIG. 3. Kinetics of b-gal expression. Cells infected with VV-LZ2 (A) or SPV-LZ4 (B) at an m.o.i. of 1 PFU per cell were lysed at different times
postinfection and subsequently assayed for b-gal activity. Units of b-gal are expressed as nmoles of ONPG hydrolyzed in 1 min at 37°C per 5 3 104
cells. The various cell lines used are indicated on the right.
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HeLa cells, where it could not be formally excluded that
the low viral titers recovered were residual input virus.
Therefore, we carried out other experiments to confirm
and further characterize the in vitro host range of SPV.
We tested the ability of SPV-LZ4 to grow and spread in
several cell monolayers by performing plaque assays
staining with X-gal (Fig. 5). SPV-LZ4 formed large blue
plaques in ESK-4 and CV-1 cells with roughly the same
plaquing efficiency. Small or diffuse plaques formed in
BSC-1, HeLa, and BHK-21 cell monolayers with a low
plaquing efficiency. Since detectable plaques arise from
multiple rounds of viral replication, plaque formation was
an unequivocal indication of viral multiplication in these
cell monolayers. No blue plaques were detected in RK-
13, SIRC, and MDBK cell monolayers, in agreement with
virus production results (Fig. 4A).
DISCUSSION
In this communication we describe the development of
a cloning system for the generation of recombinant SPV
by adapting procedures devised for the genetic manip-
ulation of other poxviruses. This is the first full descrip-
tion of such a cloning system, although SPV recombi-
nants have reportedly been obtained by inactivation of
the thymidine kinase (TK) gene (van der Leek et al.,
1994). The conventional procedure for the isolation of
recombinant poxviruses based on TK inactivation results
in a severe attenuation of the virus (Buller et al., 1985).
Because the rare vaccine-associated risks are a major
concern in vaccine development, attenuation is regarded
as a desirable feature of vaccine vectors based on re-
combinant VV, and efforts are directed to develop highly
attenuated strains with decreased virulence (Moss, 1996;
Paoletti, 1996; Tartaglia et al., 1992). However, in the case
of SPV, the virus naturally exhibits a limited pathogenicity
(Kasza and Griesemer, 1962; Meyer and Conroy, 1972;
Tuboly et al., 1993), and therefore further attenuation by
gene disruption might not be desirable, since it could
result in a loss of vaccine efficacy. With this in mind we
developed a SPV cloning system such that insertion or
FIG. 4. Virus production in different cell lines. (A) Virus production. Monolayers of the indicated cell lines were infected at a m.o.i. of 0.1 PFU per
cell with VV-LZ2 or SPV-LZ4. After 3 days (for VV-LZ2-infected cells) or 6 days (for SPV-LZ4-infected cells) cells were harvested. Virus titers were
subsequently determined by plaque assay on BSC-1 (for VV-LZ2) or ESK-4 (for SPV-LZ4) monolayers. Virus titers at 0 time (after the adsorption period)
were in all cases under 1 3 104 PFU/2 3 105 cells. (B) Titers obtained after serial passages of SPV-LZ4. The initial culture was infected at a m.o.i.
of 0.25 PFU per cell. In subsequent infections, one half of the material from the previous culture was used for infection. Titers were finally determined
on ESK-4 monolayers.
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selection would not rely on the inactivation of any viral
gene. If necessary, the system can be used in combina-
tion with defined modifications of the viral genome re-
sulting in altered biological characteristics of the virus or
enhanced immunogenicity of the foreign protein.
In addition to the insertion system, poxviral transcrip-
tional regulators are required to ensure expression of the
foreign gene. Since there is no available information
concerning SPV promoters, we performed transient ex-
pression assays to evaluate promoter function of se-
quences derived from VV in a SPV context. Several facts
led us to anticipate that VV promoters could be useful in
directing high-level expression of genes. First, the limited
sequence information from the SPV genome reveals that
many VV regulatory features are conserved (Massung et
al., 1993). Second, the VV 7.5 early/late promoter has
been shown to be functional in a SPV background, al-
though no expression data are available (van der Leek et
al., 1994). Third, several studies have reported cross-
recognition of promoter elements between different pox-
virus genera (Boyle, 1992; Boyle and Coupar, 1986; Ku-
mar and Boyle, 1990; Pearson et al., 1991; Prideaux et al.,
1990). Our results demonstrate that strong VV promoters
P11 and the synthetic promoter PE/L are functional in
SPV-infected cells, indicating good cross-recognition of
these VV promoters by SPV RNA polymerase.
The LacZ gene was chosen as a convenient marker
gene for the characterization of the SPV cloning system
because it provides a simple and reliable method for the
detection of recombinant viruses (Chakrabarti et al.,
1985; Liu et al., 1990; Panicali et al., 1986; Spehner et al.,
1990). Furthermore, a number of studies have validated
the b-gal assay for measuring promoter strength as well
as for comparing expression levels induced by different
recombinant poxvirus (Boyle, 1992; Davison and Moss,
1989a,b; Kumar and Boyle, 1990).
Recombinant SPV expressing b-gal offered new op-
portunities for analyzing SPV host range in cell culture. A
number of studies have reported the host-restricted na-
ture of SPV. Early studies reported that swine are the only
host for SPV and that other species, including chick
embryos, several laboratory animals, and humans, are
not susceptible to the virus (Datt, 1964; Meyer and Con-
roy, 1972; Schwarte and Biester, 1941). Moreover, only
porcine cell cultures have been reported to be permis-
sive for SPV as no propagation of the virus has been
detected in primary cell cultures (Kasza et al., 1960; Mayr,
1959) or in established cell lines (Foley et al., 1991; Garg
and Meyer, 1972) derived from other species. Our results
clearly show SPV gene expression, replication, and
spread in certain nonporcine cell lines. The cumulative
evidence presented in this study indicates that although
SPV grows more efficiently in porcine-derived cell lines,
the virus is able to propagate to some extent in most of
the cell lines tested.
The observation that SPV can grow in a wide range of
cell lines was surprising in light of the previous literature.
Much of the information about SPV host range is derived
from attempts to adapt SPV taken from lesions to cell
cultures from different species. It is possible that these
FIG. 5. Plaquing of SPV-LZ4 on different cell lines. Serial dilutions of a SPV-LZ4 crude virus stock were used to infect monolayers of the cell lines
indicated. Virus dilutions used for each cell line were 1026 for ESK-4 and CV-1, 1025 for BSC-1 and BHK-21, and 1024 for HeLa, MDBK, RK13, and SIRC.
Plaquing efficiency, relative to that obtained on ESK-4 cells, was 0.73 for CV-1 cells, 0.15 for BHK-21 cells, 0.08 for BSC-1 cells, and 0.07 for Hela cells.
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previous studies were hampered by technical difficulties
related to the slow and limited growth of the virus (Mas-
sung and Moyer, 1991), its lower level of replication
compared with other poxviruses, and the lack of a reli-
able SPV plaque assay. Indeed, in our hands the level of
replication in some cell lines was not enough to sustain
repeated passaging in cell lines in which SPV replicates
to a low level (Fig. 4B), and therefore failed attempts to
grow SPV in cell cultures by blind passage should not be
considered a bona fide indication of host restriction of
the virus. It is unclear whether blind passages of SPV
natural isolates performed in several studies represent
in all cases an authentic adaptation of the virus or
whether several passages are required to obtain enough
virus to produce a generalized cythopathic effect. Inter-
estingly, in one report, cythopatic effect was reported at
the first passage of a natural isolate in PK15 and Vero
cells, although repeated passaging in Vero cells could
not be maintained (Paton et al., 1990), suggesting that no
adaptation was required for this natural isolate. In our
experience, monolayer conditions and cell density can
greatly influence the appearance and the yield of an
infection (data not shown).
SPV replicated to very different levels in different cell
lines. No evidence of SPV replication could be detected
in bovine MDBK cells, a cell line which is also nonper-
missive for VV (Hruby et al., 1980). This result was in
agreement with previous reports of failed adaptation of
SPV to MDBK cells (Foley et al., 1991; Garg and Meyer,
1972). Rabbit SIRC and RK-13 cells also failed to support
detectable SPV replication. In this regard it is interesting
to note that SPV apparently lacks the homolog of VV host
range gene K1L (Massung et al., 1993), which is required
for VV replication in RK-13 cells (Perkus et al., 1990).
Recombinant SPVs have been considered promising
vaccines for pig diseases (Foley et al., 1991; Tuboly et al.,
1993; van der Leek et al., 1994). In this respect, a recom-
binant SPV expressing b-gal represents a new tool for
characterizing and potentially improving its properties as
a vaccine vector. Two important issues relevant to the
use of poxviruses as vaccines are their efficacy and
safety. Several findings presented here are pertinent to
vaccine development. First, in general SPV was more
efficient than VV in directing foreign gene expression in
porcine cells. Thus, SPV may be a better vector for
promoting high-level expression of immunogens in pigs,
and indeed SPV appears more efficient than VV in infect-
ing swine by different routes of inoculation (Datt, 1964).
Second, SPV host restriction was not as narrow as an-
ticipated, and this trait should be carefully considered in
connection with vaccine safety issues. Similar to the
orthopoxviruses, it is possible that one or several host
range genes present in SPV modulate the ability of the
virus to carry out gene expression in different cells.
Therefore, one might be able to genetically curtail SPV
host range by deleting SPV genes, to make more re-
stricted vaccine vectors for swine.
It is also tempting to speculate that SPV tropism or
replication efficiency could be extended by insertion of
host range genes from other poxviruses, as is the case
with ectromelia virus, whose host range can be altered
by insertion of a host range gene from other orthopoxvi-
ruses (Chen et al., 1992). SPV and VV are immunologi-
cally and genetically distinct (De Boer, 1975; Massung
and Moyer, 1991; Ouchi et al., 1992), and therefore it can
potentially be used for heterologous boosting in combi-
nation with other poxviruses.
The reported in vivo host restriction of SPV to swine
(Datt, 1964; Schwarte and Biester, 1941), its natural host,
seems to be more strict that the in vitro host range of the
virus. This is also the case with other host-restricted
poxviruses, such as ectromelia and smallpox (Fenner et
al., 1989), which also display a wider host range in cell
culture than in animals. Much work has been carried out
in elucidating the viral determinants of host range in cell
culture, and these differences indicate that additional
determinants are acting in vivo. Obviously, genes in-
volved in interactions of the virus with the immune de-
fenses or spread within tissues are good candidates for
modulating the in vivo host range. Awaiting more exper-
imentation, the determinants of host restriction in vivo
and in vitro remain an interesting problem in the biology
of poxviruses.
MATERIALS AND METHODS
Viruses and cell lines
SPV (Kasza strain) was obtained from the American
Type Culture Collection (ATCC). vRB12, a non-plaque-
forming mutant of VV, WR strain (Blasco and Moss, 1991,
1992), was used as the parental virus from which a
recombinant VV expressing b-gal (VV-LZ2) was con-
structed.
All the cell lines used in this study were obtained from
the American Type Culture Collection. SPV was grown in
PK-15 (porcine kidney) cells and VV in CV-1 (African
green monkey kidney) cells. Plaque assays for SPV were
carried out on ESK-4 (embryonic porcine kidney) cell
monolayers and VV plaque assays were performed on
BSC-1 (African green monkey kidney) cells. The following
cell lines were also used: ST (porcine testis), IBRS (por-
cine kidney), HeLa (human cervix), BHK-21 (Syrian ham-
ster kidney), RK-13 (rabbit kidney), SIRC (rabbit cornea),
and MDBK (bovine kidney). All cell lines were grown in
Eagle’s minimum essential medium (EMEM) except
ESK-4, ST, BHK-21, and MDBK cells, which were grown in
Dulbecco’s EMEM (DEMEM). Unless noted otherwise, all
media contained 5% fetal bovine serum (FBS), 2 mM
L-glutamine, 100 U/ml penicillin, and 100 mg/ml strepto-
mycin. ESK-4, ST, BHK-21, and MDBK cells were supple-
mented with nonessential amino acids.
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Virus growth
SPV stocks were prepared in PK-15 cells. The cultures
were infected with plaque-purified virus and incubated at
37°C until complete cytopathic effect (CPE) was
reached. Virus was liberated from cells by three succes-
sive cycles of freeze–thawing, sonicated briefly, and
stored in aliquots at 270°C. SPV titers were determined
by plaque formation on ESK-4 cell monolayers. Plaque
assays were performed in liquid medium (6–7 days) or
under a 0.6–1.0% low-melting-point agarose overlay (8–9
days), until visible plaques appeared after staining with
crystal violet. For b-gal staining in plaque assays, a
second agarose overlay containing 300 mg/ml of X-gal
was added at 6 days postinfection, and blue plaques
were visible after a further 6- to 12-h incubation at 37°C.
VV mutant vRB12 used in this study was amplified by
infecting cultures at high multiplicity of infection (m.o.i.),
whereas growth and plaquing of recombinant VV-LZ2
were carried out following standard procedures (Earl and
Moss, 1991).
SPV and VV host range in vitro were compared by
infecting different cell monolayers containing 2 3 105
cells at a m.o.i. of approximately 0.1 PFU/cell for 1 h at
37°C. After the adsorption period, virus inocula were
removed, and the cultures were then washed once with
prewarmed DMEM and incubated with fresh medium
(2.5% FBS in DMEM). Infections were arrested by freez-
ing the cultures at time 0 (after the adsorption period), 3
days (for VV) or 6 days (for SPV) postinfection. Virus titers
were subsequently determined by plaque assay on
BSC-1 (for VV) or ESK-4 (for SPV) monolayers.
Enzymes and reagents
Restriction enzymes, T4 DNA ligase, and alkaline
phosphatase from calf intestine were supplied by New
England Biolabs or Boehringer-Mannheim and used
as specified by the manufacturers. PCR reactions for
the generation of DNA flanks of SPV genome were
performed with Pfu DNA polymerase from Stratagene.
The Expand Long Template PCR system from Boehr-
inger was used in the PCR reactions to analyze the
recombinant SPV genomic structure. Lipofectin re-
agent was supplied by Gibco-BRL. Purified Esche-
richia coli b-galactosidase (grade VIII) and o-nitrophe-
nyl-b-D-galactopyranoside (ONPG) were purchased
from Sigma, and 5-bromo-4-chloro-3-indolyl-b-D-galac-
topyranoside (X-gal) from Biomol.
Construction of plasmids
Figure 1 depicts the overall cloning scheme. Plasmid
pUCLZ-7, containing the LacZ gene downstream of a VV
early/late synthetic promoter, was constructed as fol-
lows: a DNA fragment containing the promoter sequence
and several restriction sites was generated by annealing
the following complementary oligonucleotides in which
the overhanging cohesive ends are underlined: 59-GATC-
CATCTCGAGTTATTTATATTCCAAAAAAAAAAAATAA-
AATTTCAATTTTTCCATGGGCTAGCAGATCTAAGCTT-39
and 59-GATCAAGCTTAGATCTGCTAGCCCATGGAAAAA-
TTGAAATTTTATTTTTTTTTTTTGGAATATAAATAACTCG-
AGATG-39. This DNA fragment was cloned into the
BamHI restriction site of plasmid pUC19 to generate
pUCPTS-3. Cloning of the oligonucleotide recreates only
one BamHI site just downstream of the VV promoter, and
therefore pUCPTS-3 contains a unique BamHI site. A
BamHI fragment derived from plasmid pSC11 (Chakrabarti
et al., 1985), containing the LacZ gene, was then inserted
into the BamHI site of pUCPTS-3 to generate pUCLZ-7.
The b-gal insertion/expression vector, plasmid pG-
SPV-LZ4, was constructed by placing the LacZ cassette
between SPV genomic sequences for homologous re-
combination. To generate the DNA flanks of SPV ge-
nome, two sequences from the intergenic region that
separates ORFs C18L and C19L in the SPV HindIII C
DNA fragment (Massung et al., 1993) were amplified by
PCR using primers 59-CAAATATTCTAGATATTCAA-39
(XbaI site underlined) and 59-GTAAATAAGCTTCTCTT-
TTT-39 (HindIII site underlined) for the creation of a
509-bp right flank, and primers 59-AAAAGAGATCCTATT-
TACA-39 (BamHI site underlined) and 59-AATATACT-
GAGCTCATACTA-39 (SacI site underlined) for the cre-
ation of a 486-bp left flank. After PCR amplification and
digestion with the appropriate restriction enzymes, the
flanking sequences were cloned sequentially into unique
restriction sites in plasmid pGEM-7. Finally, the resulting
plasmid, pGSPV, was digested with HindIII and ligated to
a HindIII fragment containing the promoter-driven LacZ
gene derived from pUCLZ-7.
Plasmid pRB20-LZ1, used to insert the LacZ gene into
VV genome, was constructed from plasmid pRB20, a
derivative of pRB19 (Blasco and Moss, 1995) in which an
EcoRI fragment containing the gpt cassette had been
removed (unpublished results). A HindIII fragment con-
taining the LacZ cassette was isolated from plasmid
pUCLZ-7 and ligated to HindIII-digested pRB20.
Isolation of SPV and VV recombinants
The procedure used to construct a SPV recombinant
expressing b-gal (SPV-LZ4) was adapted from methods
previously described for VV (Earl and Moss, 1991). Pre-
confluent monolayers of PK-15 cells grown in T-25 flasks
were infected with SPV at a m.o.i. of about 0.2 PFU. The
virus was allowed to adsorb for 1 h at 37°C and cells
were transfected with 5 mg of calcium phosphate-precip-
itated plasmid DNA. Eighteen hours after infection, the
transfection medium was removed and replaced with
fresh EMEM–2.5% FBS, and cells were incubated at
37°C until complete CPE was reached (usually 6–7
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days). Recombinant viruses expressing b-gal were iso-
lated by plaque assay on monolayers of ESK-4 cells in
the presence X-gal. Isolation of recombinant viruses was
carried out by four to five sequential rounds of plaque
purification. The genomic structure of recombinant vi-
ruses was analyzed by PCR, using primers derived from
the SPV genomic sequence flanking the insertion site
59-TGACCCTAAATATGTACCAGAAATAATACG-39 (JB9)
and 59-TCGTAAATATGACATAAAACCATTATTTATTG-39
(JB10). The PCR amplification of a 4.3-kb fragment, in-
stead of the 1.1 fragment obtained from wild-type SPV,
was indicative of a correct insertion of the LacZ gene.
A VV recombinant expressing the LacZ gene (VV-LZ2)
was isolated using a selection method based on plaque
formation (Blasco and Moss, 1995). Briefly, the system
consists of two components: a mutant VV lacking the
vp37 gene, which has a nonplaquing phenotype, and a
plasmid vector (pRB20) that, through homologous recom-
bination, can simultaneously introduce a foreign gene
(LacZ in this case) and a functional vp37 gene that
repairs the nonplaquing mutation in the VV genome.
b-Gal assays
In transient expression assays, monolayers of PK-15
cells grown on 24-multiwell trays were inoculated with
wild-type virus (SPV or VV) at a m.o.i. of approximately 5
PFU/cell. The virus inoculum was removed after 1 h and
cells were then transfected with various amounts of
plasmid DNA, using lipofectin reagent as recommended
by the manufacturer. After 5 h, transfection medium was
removed and replaced with EMEM–2.5% FBS without
phenol red, and cells were further incubated at 37°C for
96 h. At this time infection was arrested by freezing the
cultures. Detection of b-gal activity was performed es-
sentially as described by Davison and Moss (1989a,b).
Infected cells in culture trays were frozen and thawed,
scraped into the medium, and disrupted by adding 25 ml
of chloroform and 25 ml of 0.05% sodium dodecyl sulfate.
Portions of the lysates were incubated with Z buffer–
ONPG solution (60 mM Na2HPO4, 40 mM NaH2PO4, 10
mM KCl, 1 mM MgSO4, 40 mM 2-Mercaptoethanol, 4
mg/ml ONPG) at room temperature. The yellow color
which developed after 15–30 min was recorded as ab-
sorbance at 405 nm. b-Gal activity present in each sam-
ple was estimated with reference to a standard curve
obtained with commercial E. coli b-gal, after subtracting
the background values obtained with lysates from in-
fected cells that had been transfected with pUC19 con-
trol plasmid.
Expression of b-gal by the recombinant viruses SPV-
LZ4 and VV-LZ2 was assayed as described above with
the following modifications. Monolayers of different cell
lines grown on 96-multiwell trays were infected with the
recombinant viruses at a m.o.i. of about 1 PFU/cell. After
removing the inocula and washing the monolayer once,
cells were incubated with EMEM–2.5% FBS without phe-
nol red at 37°C in the presence or the absence of 40
mg/ml of araC. At the various times the cultures were
frozen and cell lysates were assayed for b-gal activity
directly in the 96-multiwell trays. Quantitation of b-gal
present in the samples was performed as described
above, after subtracting background values obtained
with lysates from uninfected cells.
Serial passages of SPV
Different cell line monolayers containing 1 3 106 cells
were inoculated at a m.o.i. of about 0.25 PFU/cell. After a
2-h adsorption period at 37°C, the inoculum was re-
moved and the monolayers were washed once to re-
move unadsorbed virus. Fresh medium was added and
the cultures were incubated at 37°C for 6 days. At this
time, cells were removed from the plate by scraping and
lysed by three successive cycles of freeze–thawing, fol-
lowed by mild sonication. One half of each lysate was
then used to inoculate a fresh monolayer of the same cell
line. This procedure was repeated for six sequential
passages. Finally, samples from each passage were
assayed for the presence of infectious virus by plaque
titration on ESK-4 monolayers.
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